理解的对吗？

A contemporary analysis of the PROTECT cohort found incident hyperkalemia (K≥5.5) in patients hospitalized for acute decompensated heart failure was not associated with poor outcomes. However, hyperkalemia was associated with dose reduction of MRAs in 15% of patients but did not impact dosing of other RAAS inhibitors. Patients who required dose reduction or discontinuation of RAAS inhibition had increased mortality at 180 days with an adjusted hazard ratio (HR) of 1.97.

同时对PROTECT队列的分析发现：急性失代偿性心力衰竭住院患者发生高钾血症(K≥5.5)与不良预后无关。然而，在15%的患者中，因高钾血症而使得MRAS用药剂量减少，但不影响其他RAAS抑制剂正常使用剂量。需要减少剂量或停止RAAS抑制剂的患者在180天时死亡率增加，调整后的危险比（HR）为1.97。

老师，这句话是不是 ---- 然而，在15%的患者中，因高钾血症而使得MRAS用药剂量减少，但不影响其他RAAS抑制剂正常使用剂量？谢谢  

盐皮质激素受体拮抗剂（MRAs）